|
|
Volumn 341, Issue 7782, 2010, Pages 1076-1078
|
|
What makes an orphan drug?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3,4 DIAMINOPYRIDINE;
AMIFAMPRIDINE;
CARBAMYLGLUTAMATE;
GLUTAMIC ACID;
ORPHAN DRUG;
UNCLASSIFIED DRUG;
CONGENITAL MYASTHENIC SYNDROME;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG SAFETY;
HUMAN;
LAMBERT EATON MYASTHENIC SYNDROME;
NEUROMUSCULAR JUNCTION DISORDER;
PRIMARY MEDICAL CARE;
PRIORITY JOURNAL;
RARE DISEASE;
SHORT SURVEY;
DRUG APPROVAL;
DRUG COSTS;
GREAT BRITAIN;
ORPHAN DRUG PRODUCTION;
|
|
EID: 78449284387
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.c6459 Document Type: Short Survey |
|
Times cited : (16)
|
|
References (5)
|
